Kairos Pharma to Showcase Oncology Research at D. Boral Capital Global Conference
Kairos Pharma will participate in the D. Boral Capital Inaugural Global Conference, offering investors insights into its innovative cancer therapeutic research, focusing on overcoming drug resistance with its lead candidate ENV105.
Kairos Pharma Ltd., a biopharmaceutical company specializing in oncology therapeutics, will present its groundbreaking cancer research at the D. Boral Capital Inaugural Global Conference on May 14, 2025. The event, taking place at The Plaza Hotel in New York City, will provide an opportunity for CEO and Chairman John Yu, MD, to engage with investors through one-on-one meetings.
The company's strategic focus centers on utilizing structural biology to address critical challenges in cancer treatment, specifically drug resistance and immune suppression. Its lead candidate, ENV105, represents a potentially significant advancement in cancer therapy by targeting CD105, a protein identified as a key driver of treatment resistance.
ENV105 aims to reverse drug resistance mechanisms by specifically targeting CD105, with the potential to restore the effectiveness of standard cancer treatments across multiple cancer types. Currently, the drug candidate is undergoing clinical trials, including a Phase 2 trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer.
The conference presentation offers investors and medical researchers an opportunity to gain deeper insights into Kairos Pharma's innovative approach to addressing significant unmet medical needs in oncology. By targeting the underlying mechanisms of treatment resistance, ENV105 could represent a transformative approach to cancer therapy.